Medel Roger Md Buys Shares of OPK $OPK

Editorial illustration for OPKO Health, Inc. (OPK)

Key Points

  • Medel Roger Md bought 30,000 shares of OPKO Health, Inc. ($OPK).
  • $OPK last traded around $1.43.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Medel Roger Md, insider at OPKO Health, Inc. ($OPK), bought 30,000 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

OPKO Health, Inc. Stock Down 3.4%

Shares of OPKO Health, Inc. ($OPK) traded around $1.43 on Tuesday, down 3.4% for the day.

Last price$1.43
Market cap$1.10B
Forward P/E-5.35
PEG ratio93.65
Beta1.49
52-week low$0.98
52-week high$1.73
50-day MA$1.38
200-day MA$1.29
Current ratio3.35
Quick ratio2.65
Debt-to-equity0.34

OPKO Health, Inc. Earnings

EPS (ttm)-$0.07
Revenue (ttm)$587.90M
Revenue growth4.30%
Net margin-12.40%
Return on equity-5.88%
Next earningsOct 28, 2026

Analysts Set New Price Targets

Average target$4.38
High target$8.50
Low target$3
Analysts covering4

About OPKO Health, Inc.

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

ExchangeNasdaqGS
SectorHealthcare
IndustryDiagnostics & Research
HeadquartersMiami, FL
CEODr. Phillip Frost M.D., Ph.D.
Employees2,275

Get OPKO Health, Inc. alerts

New 13F filings, insider trades, and analyst moves on $OPK, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.